92 related articles for article (PubMed ID: 3469468)
61. Computer-assisted morphonuclear characterization of radiotherapy-induced effects in MXT mouse mammary adenocarcinomas surviving earlier radiotherapy.
Francisco J; Pauwels O; Simon S; Gasperin P; Van Houtte P; Pasteels JL; Kiss R
Int J Radiat Oncol Biol Phys; 1995 May; 32(2):409-19. PubMed ID: 7751183
[TBL] [Abstract][Full Text] [Related]
62. In vitro biotransformation of estradiol by explant cultures of murine mammary tissues.
Telang NT; Bradlow HL; Kurihara H; Osborne MP
Breast Cancer Res Treat; 1989 Mar; 13(2):173-81. PubMed ID: 2730963
[TBL] [Abstract][Full Text] [Related]
63. Morphology of MXT mouse mammary tumors. Correlation with growth characteristics and hormone sensitivity.
Danguy A; Kiss R; Leclercq G; Heuson JC; Pasteels JL
Eur J Cancer Clin Oncol; 1986 Jan; 22(1):69-75. PubMed ID: 3754213
[TBL] [Abstract][Full Text] [Related]
64. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part 1: The MXT-M-3.2 breast cancer stimulates the growth of an identical second graft; [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplat inum (II) inhibits this process.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 2000 Mar; 333(2-3):69-71. PubMed ID: 10783521
[TBL] [Abstract][Full Text] [Related]
65. In vivo characterization by means of digital cell image analysis of early-induced fractionated radiotherapy effects on the MXT mouse mammary tumor.
El-Khattabi O; Pauwels O; Simon S; Gasperin P; Frühling J; Kiss R; Van Houtte P
Int J Radiat Oncol Biol Phys; 1997 Feb; 37(3):673-8. PubMed ID: 9112466
[TBL] [Abstract][Full Text] [Related]
66. Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo.
Beckenlehner K; Bannke S; Spruss T; Bernhardt G; Schönenberg H; Schiess W
J Cancer Res Clin Oncol; 1992; 118(8):591-6. PubMed ID: 1517281
[TBL] [Abstract][Full Text] [Related]
67. Lack of growth of a pregnancy-dependent mouse mammary tumor (TPDMT-4) in the absence of pituitary hormones.
Matsuzawa A; Yamamoto T
J Natl Cancer Inst; 1977 Apr; 58(4):1087-91. PubMed ID: 845979
[TBL] [Abstract][Full Text] [Related]
68. The relationship of blood vessel proximity and time after radiolabeled thymidine administration to tumor cell population kinetics in a transplanted mouse mammary tumor.
Pavelic ZP; Allen LM; Mihich E
Am J Pathol; 1981 Jan; 102(1):84-9. PubMed ID: 7468761
[TBL] [Abstract][Full Text] [Related]
69. Dose-dependent effect of 17 beta-estradiol determined by growth curves and flow cytometric DNA analysis of a human breast carcinoma (T61) grown in nude mice.
Brünner N; Spang-Thomsen M; Vindeløv L; Nielsen A; Engelholm SA; Svenstrup B
Exp Cell Biol; 1985; 53(4):220-32. PubMed ID: 4029478
[TBL] [Abstract][Full Text] [Related]
70. Extinction of experimental mammary cancer. I. Estradiol-17beta and progesterone.
HUGGINS C; MOON RC; MORII S
Proc Natl Acad Sci U S A; 1962 Mar; 48(3):379-86. PubMed ID: 14449778
[No Abstract] [Full Text] [Related]
71. Increased survival due to radioactive estradiol in mice with C3HBA or BW 10232 tumors.
Thysen B; Rettura G; Padawer J; Gatz M; Levenson SM; Seifter E
Cancer Chemother Pharmacol; 1982; 8(1):23-6. PubMed ID: 7046975
[TBL] [Abstract][Full Text] [Related]
72. Redifferentiation of cancer cells: bestatin, estradiol, and prostaglandin D2.
Okuyama S; Mishina H; Maki T
Ann N Y Acad Sci; 1985; 459():293-307. PubMed ID: 3868328
[TBL] [Abstract][Full Text] [Related]
73. Mxt mammary-tumor treatment with a high-temperature radiofrequency ablation device.
Zlotta A; Kiss R; Dedecker R; Schulman C
Int J Oncol; 1995 Oct; 7(4):863-9. PubMed ID: 21552915
[TBL] [Abstract][Full Text] [Related]
74. Monitoring of radiotherapy-induced morphonuclear modifications in the MXT mouse mammary carcinoma by means of digital cell image analysis.
Gasperin P; Gozy M; Pauwels O; Frühling J; Van Houtte P; Pasteels JL; Kiss R
Int J Radiat Oncol Biol Phys; 1992; 22(5):979-87. PubMed ID: 1555990
[TBL] [Abstract][Full Text] [Related]
75. Progesterone enhancement of mammary tumor development as a model of co-carcinogenesis.
Poel WE
Br J Cancer; 1968 Dec; 22(4):867-73. PubMed ID: 5705149
[No Abstract] [Full Text] [Related]
76. Influence of L-thyroxine, L-triiodothyronine, thyroid stimulating hormone, or estradiol on the cell kinetics of cultured mammary cancer cells.
de Launoit Y; Kiss R
In Vitro Cell Dev Biol; 1989 Jul; 25(7):585-91. PubMed ID: 2753847
[TBL] [Abstract][Full Text] [Related]
77. In vivo influence of androgens on the cell kinetics and chromatin pattern of the MXT mouse mammary tumor treated or not by aminoglutethimide.
de Launoit Y; Kiss R
J Cancer Res Clin Oncol; 1989; 115(2):129-38. PubMed ID: 2469677
[TBL] [Abstract][Full Text] [Related]
78. Synergism or antagonism between estradiol and progesterone on the cell kinetic parameters of the MXT mouse mammary tumor.
Kiss R; Danguy AJ; Heuson JC; Paridaens RJ
J Natl Cancer Inst; 1987 Mar; 78(3):573-9. PubMed ID: 3469468
[TBL] [Abstract][Full Text] [Related]
79. Effect of prolactin and estradiol on cell proliferation in the uterus and the MXT mouse mammary neoplasm.
Kiss R; de Launoit Y; L'Hermite-Balériaux M; L'Hermite M; Paridaens RJ; Danguy AJ; Pasteels JL
J Natl Cancer Inst; 1987 May; 78(5):993-8. PubMed ID: 3472006
[TBL] [Abstract][Full Text] [Related]
80. Hormonal regulation of uterine epithelial cell proliferation. I. Effects of estradiol or progesterone administered separately.
Kiss R; Lenglet G; Pasteels JL; Danguy A
In Vivo; 1987; 1(5):281-9. PubMed ID: 2979795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
